Billionaire Ray Dalio’s Bridgewater’s 10 Stock Picks with Huge Upside Potential

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bridgewater Associates Stake Value: $23,649,110

Upside Potential as of May 2: 59.43%

Number of Hedge Fund Holders: 49

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops treatments for serious diseases. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos, targeting conditions like narcolepsy-related EDS and hepatic veno-occlusive disease (VOD).

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) achieved a record $4 billion in 2024 revenue, with Q4 revenue hitting $1.1 billion, its highest ever. In November, the company secured accelerated U.S. approval for Ziihera to treat second-line HER2-positive biliary tract cancer. On April 25, Jazz announced that CHMP of the EMA issued a positive opinion recommending conditional approval of zanidatamab, a HER2-targeted bispecific antibody, for advanced HER2-positive BTC. The company remains focused on strategic diversification, actively evaluating oncology, neuroscience, and rare disease assets to strengthen its pipeline.

On April 22, TD Cowen kept its Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a $100 price target. Jazz is a key player in sleep disorder treatments, competing with ALKS, AXSM, CNTA, and TAK. Its oxybate franchise earned $1.7 billion, contributing to $4.07 billion in total revenue, with a 92.36% profit margin and 6.12% growth over the past year. Analysts stress the importance of the idiopathic hypersomnia (IH) market, where Xywav is the only approved therapy.